10Nov
10Nov
eSight Opens First US Office, Bringing New Possibilities to People Living With Visual Impairments
Leading vision enhancement company, eSight, is expanding its global presence with the opening of its first office in the U.S. The Toronto-based company has chosen the Nashville, Tennessee area in order to better support its growing distribution network of low vision assistive technology specialists, retinal specialists, ophthalmologists, optometrists, and the agencies that work with members of the low vision community on a daily basis. Read more >>
06Nov
Torornto-based Esight to open Franklin office
A Toronto-based health care company has chosen Franklin for its first office outside of Canada. Vision technology firm Esight (stylized eSight) is opening an office at 330 Mallory Station Road, according to a news release. Former Nashville-based Precedent Health CEO Brian McCollum will lead the Franklin office as Esight’s chief commercial officer. Read more >>
04Nov
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice. Read more >>
03Nov
Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease
Neuraly, Inc., a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease. NLY01 is also being evaluated in patients with Parkinson’s disease in a Phase 2 trial initiated in February 2020. Read more >>
03Nov
Myomo names chief medical officer
Myomo today said it appointed Dr. Harry Kovelman as chief medical officer, effective immediately. Kovelman will be responsible for overseeing the company’s patient advocacy organization. He will work with commercial and government payer organizations to increase patient access to the MyoPro product line. Read more >>
03Nov
Advanced assistive tech device to support 2 million people in the UK with sight loss
eSight has announced that its newest vision enhancement technology, eSight 4, is now available in the UK through VisionAid Technologies, expanding its goal of providing sight to people with visual impairment worldwide. According to the European Blind Union, there’s an estimated 30 million blind or partially sighted people in Europe. In the UK alone, there are almost 2 million people living with sight loss, NHS statistics show. Read more >>
29Oct
SAM Sport’s Ability to Help Athletes Recover from Injury Without Surgery is Gaining Recognition from Enthusiasts Within the Tennis Community
SAM Sport, an FDA-cleared bio regenerative medical device that helps reduce pain associated with tendon, ligament, and muscle injuries is receiving an increased amount of attention for its ability to help tennis players recover without surgery. SAM by ZetrOZ Systems provides proven soft tissue and chronic pain relief through continuous ultrasound treatment. Read more >>
29Oct
ALung and CytoAgents CEOs talk pandemic’s impact on funding, trials
At 3 Rivers Venture Fair, panel discussion, CEOs address what happened when they changed direction due to Covid-19. Including CytoAgents. Read more >>
29Oct